Get the content you want anytime you want.
REGISTER NOW | SIGN IN

Healthcare professionals and thought leaders share their knowledge and insights on an array of infectious disease topics

Latest Videos

Gram-Positive NIs: Costs of Lipoglycopeptide Therapy
Peter L. Salgo, MD; Debra Goff, PharmD, FCCP; Andrew Shorr, MD; Sandy J. Estrada Lopez, PharmD, BCPS (AQID); and Jason Pogue, PharmD, BCPS-AQID, identify the balance that needs to be struck between cost and effectiveness in the context of lipoglycopeptide therapy for gram-positive nosocomial infections.
Battling Resistance to HIV Therapy: New Drugs in the Pipeline
Joseph Eron, MD, explains how some individuals acquire resistance to HIV therapy and discusses new drugs in the pipeline that are effective against resistant virus.
<i>Pseudomonas</i> Infections: Nuancing the Use of Antibiotics
Marin Hristos Kollef, MD; Peter L. Salgo, MD; Andrew Shorr, MD; and Yoav Golan, MD, share insight on the appropriate approach to using antibiotics when treating pseudomonas infections at multiple levels of care.
What Can Physicians Do If Their Patient Declines Getting Tested for HIV?
Colleen Kelley, MD, stresses the importance of routinizing HIV testing and shares what physicians can do if their patient declines the option to get tested.
How Can Mobile Apps Be Used to Improve Patient Outcomes?
Debra Goff, PharmD, FCCP, explains how mobile apps are being used by health care providers to improve patient outcomes.
Cell Phones: Potential Vectors for <i>C. diff</i>?
Barley Chironda, RPN, CIC, infection control specialist at Clorox Healthcare, explains how cell phones and smart devices can potentially serve as a vector for C. diff.
Gram-Positive NIs: Nuancing Lipoglycopeptide Therapy
Peter L. Salgo, MD; Sandy J. Estrada Lopez, PharmD, BCPS (AQID); Jason Pogue, PharmD, BCPS-AQID; Andrew Shorr, MD; and Debra Goff, PharmD, FCCP, reflect on the caveats in lipoglycopeptide therapy for gram-positive nosocomial infections and emphasize that this is a different, not overarchingly effective, class of drugs.
When Can Clinicians Expect Long-Acting Injectable ART?
Joseph Eron, MD, discusses when clinicians may expect to have access to long-acting injectable ART and the different opportunities it offers for individuals with HIV.
FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.